Free shipping across Canada on orders over $200 CAD Shop now

Retatrutide vs. Tirzepatide: A Research Comparison

July 18, 2026

Retatrutide and Tirzepatide are metabolic research peptides in the incretin class, and they are often compared because both act on multiple receptors rather than one. This overview explains how they differ by receptor target and where each fits in metabolic research. It describes laboratory research only.

Tirzepatide: a dual agonist

Tirzepatide is studied as a dual agonist, engaging both the GIP and GLP-1 receptors. These two incretin pathways are central to research on glucose regulation and energy balance, and combining them in a single molecule is the defining feature of this compound.

Retatrutide: a triple agonist

Retatrutide extends the concept a step further as a triple agonist, adding activity at the glucagon receptor alongside GIP and GLP-1. The additional glucagon pathway is what distinguishes it from dual agonists in metabolic research models.

Key differences

  • Receptor targets: Tirzepatide engages GIP and GLP-1; Retatrutide engages GIP, GLP-1, and glucagon.
  • Class: Tirzepatide is a dual incretin agonist; Retatrutide is a triple agonist.
  • Research angle: the extra glucagon activity makes Retatrutide of particular interest in energy-expenditure research models.
  • Form: both are lyophilized peptides reconstituted before laboratory use.

Where Cagrilintide fits

A related metabolic research peptide, Cagrilintide, is an amylin analog studied on a different pathway again. It is sometimes examined alongside GLP-1 class compounds in combination metabolic research.

Research context and handling

New to this area? Start with Peptides 101 or return to the knowledge hub.


Research Use Only. This comparison is provided for laboratory research context only. It is not medical advice and does not describe or recommend human or animal use. All Helixa Biotech products are supplied strictly for in-vitro laboratory research.